natgillin/translations-raw huggingface dataset:
The antibody of any one of claim 1 or 2 wherein said killing and/or inhibition of one or more activities of cells is induced by binding of said antibody to GT468 expressed by said cells and/or associated with the surface of said cells, preferably by binding of said antibody to the extracellular domain of GT468 expressed by said cells and/or associated with the surface of said cells. 
Antitijelo iz patentnog zahtjeva 1 gdje je spomenuta inhibicija proliferacije stanica inducirana vezivanjem spomenutog antitijela za protein koji sadrži aminokiselinsku sekvencu sa SEK. ID BR: 2 eksprimiranog od strane spomenutih stanica i/ili vezanog sa površinom spomenutih stanica, poželjno vezivanjem spomenutog antitijela za izvanstanični domen proteina koji sadrži aminokiselinsku sekvencu sa SEK ID BR: 2 eksprimiranog od strane spomenutih stanica i/ili vezanog sa površinom spomenutih stanica.
A method according to any preceding clause, wherein the skin has a simulated stone surface. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da omotač ima površinu koja oponaša kamenu površinu.
The magnetically oriented design produced according to any one of claims 13 to 16 can be used as a security element on bank notes, value documents, identity documents, cards, tax stamps, labels, as well as for products. 
Uporaba magnetski usmjerenog uzorka izrađenog sukladno bilo kojem patentnom zahtjevu 13 do 16, naznačena time, da navedena uporaba služi za izradu sigurnosnog elementa na novčanicama, vrijednosnim dokumentima, identifikacijskim dokumentima, karticama, biljezima, oznakama ili proizvodima.
A product comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2, as a combined preparation for simultaneous, concurrent, separate or sequential use in the treatment of a patient suffering from or susceptible to a respiratory disease which responds to M3 antagonism. 
Proizvod koji sadrži (a) kortikosteroid kako je definiran u bilo kojem od patentnih zahtjeva 113 do 71 (b) antagonist M3 muskarinskih receptora kako je definiran u patentnom zahtjevu 1 ili 2, naznačen time, da je to proizvod u obliku kombiniranog pripravka za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u liječenju bolesnika koji su oboljeli ili bi mogli oboljeti od respiratorne bolesti kako je definirana u patentnom zahtjevu 11 ili 12.
Furthermore, one or more additive(s) may be added to the oil phase. Said additive(s) may be selected from the group of components consisting of a siloxane, a silane, a wax, an ester of a fatty acid, a glycerol ester and any derivative thereof or any similar synthetically produced components of this group. 
Emulzija tipa alkohol-u-ulju u skladu s bilo kojim od patentnih zahtjeva 1 do 5, gdje uljna faza također sadrži aditiv, kojeg se bira iz skupine koju čine siloksan, silan, vosak, ester masno kiseline, ester glicerola i bilo koji njegov derivat ili bilo koje slične sintetski dobivene komponente iz ove skupine.
Representative, non limiting, examples of pharmaceutical agents that can be used in the treatment of a disease state along with the formulation of the invention include antineoplastic agents, for example topoisomerase I inhibitors such as camptothecin derivatives like Irinotecan or Topotecan, anti-inflammatory compounds or inhibitors of interleukin-1 such as diacerhein, pancrelipase (such as Pancrease, Creon, Zenpep), selective phosphodiesterase-4 inhibitors used for the treatment of Chronic obstructive Pulmonary Disease (COPD) such as roflumilast or cilomilast, and compounds having anti-mitotic activities such as colchicine. 
Formulacija u skladu s patentnim zahtjevom 10, pri čemu je navedeni farmaceutski agens odabran iz grupe koja se sastoji od antineoplastičkih agenasa, na primjer inhibitora topoizomeraze I kao što su Irinotekan, protuupalnih tvari ili inhibitora interleukina-1 kao što su diacerhein, pancrelipase, selektivni inhibitor fosfodiesteraze 4 koji se koristi za liječenje kronične opstruktivne bolesti pluća (COPD) kao što je roflumilast ili cilomilast i tvari koje imaju protuupalne i anti-mitotičke aktivnosti kao što su kolhicini, Irinotekan ili njegov metabolit, posebice SN-38.
The system of claim 8, wherein the first computer network and the second computer network are the same. 
Sustav u skladu s patentnim zahtjevom 8, naznačen time što su prva računalna mreža 1 druga računalna mreža iste.
The LC conditions (Symmetry C18 column 4.6×30 mm with a particle size of 3.5 um) were linear gradient elution with eluents A (water containing 0.05% TFA) and B (acetonitrile containing 5% water and 0.035% TFA). 
LC uvjeti(Symmetry C18 stup 4,6x30 mm s česticom veličine 3.5 um) su bili elucija linearnog gradijenta s eluentima A (voda koja sadrži 0,05 %. TFA) i B (acetonitril koji sadrži 5% vode i 0,035 % TFA).
phenyl or substituted phenyl, which is selected from the group consisting 
fenila ili supstituiranog fenila, koji je odabran od grupe koja se sastoji od [image] [image] [image]
The solution was heated in a warm-water bath and DMAP (8.13g, 66.4 mmol) and DCC (25.28g, 119.6 mmol) in toluene (540mL) were added to the warm reaction mixture. 
Otopina je bila zagrijana u kupelji tople vode 1 DMAP (8.13 g, 66.4 mmol) i DCC (25.28 g, 119.6 mmol) u toluenu (540 mL) bili su dodani u vruću reakcijsku smjesu.
Ki is calculated by the Cheng and Prustoff transformation: 
Ki je kalkuliran, na primjer, pomoću Cheng and Prustoff transformacije:
All protein molecules mentioned above can be fused to other peptide or polypeptide sequences such as but not limited to linker, activating molecules or toxins. 
(i) fuzioniran s drugim peptidnim ili polipeptidnim slijedom, poput spojnice, aktivirajuće molekule ili toksina; ili
A method of preparing a solution for the treatment of constipation or faecal impaction, which method comprises combining a volume V of solution as claimed in claim 1 with water by the addition of a volume (N−1)×V of water. 
Postupak pripravljanja otopine za liječenje opstipacije ili koprostaze, naznačen time što se navedeni postupak sastoji u kombiniranju otopine u skladu s bilo kojim od patentnih zahtjeva 1 do 12 s vodom.
Composite material comprising: a plastics matrix and a filler, characterized in that the filler is grinded asbestos-cement, preferably grinded asbestos-cement waste, with the particle size between 2 micrometers and 0, 4 mm. 
- < Je punjenje mljeveni azbestni cement, po mogućnosti mljeveni otpad azbestnog cementa, u udjelu do 20% težine, po mogućnosti između 12% 1 20% težine temeljeno na ukupnoj količini kompozitnog materijala, veličine čestica između 2 mikrometra i 0,4 mm, 1
The composition of claim 1, wherein the CD3 zeta signaling domain is encoded by a nucleic acid sequence comprising SEQ ID NO: 18. 
(iv) signalno područje 4-IBB je kodirano sekvencom SEQ ID NO: 17 i signalno područje CD3 zeta je kodirano sekvencom SEQ ID NO:18;
A convenient starting material for the preparation of compounds of formula I wherein R1is O, R2 has the meaning as described above, and R3 is hydrogen is, for example, (7a)-3-methoxy-7-methylestra-1,3,5(10)-trien-17-one (i.e. the compound of formula II). 
Pogodni polazni materijal za dobivanje spojeva formule I gdje R! je O, R* ima značenje opisano gore, a R? je vodik, je, primjerice, (70)-3-metoksi-7-metilestra-1,3,5(10)-trien-17-on (tj. the spoj formule II).
e is H or any one of the side chains of the naturally occurring amino acids; is null, —O—, or —N(R)—; 
HR P20180107 T1 I eje Hili bilo koji od bočnih lanaca prirodnih aminokiselina; W; je nula, ili -N(R)-;
A method which, according to claim 1, is characterized by the detection of the hole Serum amyloid P-component (SAP, SAMP, SwissProt No: P02473) or fragments of it's amino acid sequence or of the modified protein as result of post-translation modifications. 
Metoda koja je, prema zahtjevu 1, naznačena detekcijom cijelog seruma amiloidne komponente P (SAP, SAMP, SwissProt br. P02743) ili modificiranog proteina kao posljedice posttranslacijskih modifikacija.
A method for the treatment of a vaginal fungal infection which comprises administering a topical formulation comprising an effective amount of ascorbic acid to a patient in need of such a treatment wherein said formulation is vaginally administered after completion of a standard treatment against bacterial, fungal or protozoarian infections. 
HR P20090022 T3 PATENTNI ZANITJEVI Upotreba askorbinske kiseline ili njene farmaceutski prihvatljive soli za proizvodnju pripravka za topikalnu primjenu za prevenciju i liječenje vaginalnih gljivičnih infekcija, pri čemu se spomenuti pripravak primjenjuje nakon završetka standardnog liječenja protiv bakterijskih, gljivičnih ili protozojskih infekcija.
a VEGF-binding immunoglobulin single variable domain, 
jednostruka varijabilna domena imunoglobulina koja se veže na VEGF,
The process of claim 1, wherein the pressure of the last flash vessel is below atmospheric pressure. 
Proces prema patentnom zahljevu 8, naznačen time, da je pritisak posljednje posude za isparavanje ispod atmosferskog pritiska.
and R9 taken together with nitrogen to which they are attached form a non-aromatic heterocyclic ring containing 2-6 carbon atoms which is: 
Ri R?, uzeti zajedno s dušikom na kojeg su vezani, tvore nearomatski heterociklički prsten s 2-6 atoma ugljika koji je:
In more preferable embodiment, R4a is a phenyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a halo-lower alkoxy group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a lower alkyl group, or a lower alkoxy group. 
R*"* je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, C;.4 alkilnom skupinom, halogen-C;. alkilnom skupinom, C;.4 alkoksi skupinom, halogen-C;.4 alkoksi skupinom, te mono- ili di-C;g alkilamino skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, Ci.4 alkilnom skupinom ili Ci.6 alkoksi skupinom; i
the infection is caused by an organism resistant to vancomycin; or the infection is caused by an organism resistant to an antimicrobial peptide or a biosimilar therapeutic treatment. 
(Pp) infekcija je uzrokovana organizmom otpornim na vankomicin; ili (q) infekcija je uzrokovana organizmom otpornim na antimikrobni peptid ili biosličan terapijski tretman.
The invention also provides the use of pirfenidone in the manufacture of a medicament for treating a patient suffering from fibrosis, said patient having exhibited a Grade 2 abnormality in one or both of alanine transaminase (ALT) and aspartate transaminase (AST) that is greater than 2.5-times and less than or equal to 5-times the upper limit of normal, after pirfenidone administration, wherein (a) said patient is administered pirfenidone at doses of at least 1600 mg/day. 
Pirfenidon za upotrebu u liječenju pacijenta s idiopatskom pulmonarnom fibrozom (IPF), pri čemu pacijent ima razinu 2 abnormalnosti u jednom ili više biomarkera funkcije jetre poslije davanja pirfenidona, i ima abnormalnu razinu alanin transaminaze (ALT) i/ili aspartat transaminaze (AST) koja je više od 2.5- do 5.0 -puta povećana u usporedbi s gornjom normalnom vrijednošću, poslije davanja pirfenidona, gdje (a) spomenutom pacijentu se daje pirfenidon u dozama od bar 2400 mg/dan ili 2403 mg/dan.
R10, R11 and R12 are respectively and independently hydrogen, C1-6alkyl, C3-8cycloalkyl or phenyl, wherein R11 and R12, together with the nitrogen atom attached thereto, can form 3-8 membered heterocyclic group, said C1-6alkyl, C3-8cycloalkyl, phenyl and 3-8 membered heterocyclic group can be optionally substituted with 1, 2, 3, 4, 5 or 6 substituents independently selected from the group consisting of halogen, cyano, hydroxyl and carboxyl; 
R"R"iR"? su respektivno i nezavisno vodik, C,galkil, Cagcikloalkil ili fenil, pri čemu R"1R?, zajedno s atomom dušika koji je vezan na njih, mogu tvoriti 3-8 članu heterocikličnu skupinu, spomenuti Crgalkil, C3. scikloalkil, fenil i 3-8 člana heterociklična skupina mogu izborno biti supstituirani s 1, 2, 3, 4, 5 ili 6 supstituenata nezavisno odabranih iz skupine koja se sastoji od halogena, cijano, hidroksila i karboksila;
The method according to claim 39, wherein said affection is selected from the group consisting of vaginal infections, vaginitis and dyspareunia. 
Postupak u skladu s patentnim zahtjevom 39, naznačen time što se navedena bolest bira iz skupine koju čine vaginalne infekcije, vaginitis i dispareunija.
heating the first filler material in the mold cavity to form a first panel segment; 
zagrijavanje kalupa (123) koji sadrže prvo punjenje (101) da bi se oblikovao segment panela (100) ekspanzijom prvog punjenja (101);
An isolated host cell or a non-human organism transformed or transfected with the nucleic acid molecule of claim 12 . 
Stanica ili nehumani organizam transformiran ili transfektiran molekulom nukleinske kiseline iz zahtjeva 9, pri čemu je stanica primjerice prokariotska ili eukariotska stanica, poželjno stanica sisavca ili optimalno ljudska stanica.
Examples of the arrangement are listed below: 
Datum podnošenja europske prijave patenta:
The composition of claim 1 characterized in that said monocarboxylic acid is selected from the group of formic acid, acetic acid, propionic acid, glycolic acid, lactic acid or mixtures thereof, preferably from formic acid or acetic acid, most preferably the monocarboxylic acid is formic acid. 
Pripravak prema zahtjevu 4, naznačen time što se monokarboksilna kiselina izabire između mravlje kiseline ili octene kiseline, najpoželjnije je monokarboksilna kiselina mravlja kiselina.
converting a compound of formula [48] to a compound of formula [49] 
(6) prevođenju spoja formule [48] u spoj formule [49]
In certain aspects, the present invention provides a nucleic acid molecule comprising a nucleotide sequence which encodes an elastase protein (including but not limited to a protein of any one of SEQ ID NOS: 6-9, 64-69, 88-91, or 98-103) comprising (i) an elastase propeptide comprising an activation peptide sequence comprising an elastase recognition sequence operably linked to (ii) the amino acid sequence of a protein having elastase activity. 
Autoaktivacijski protein proelastaze koji sadrži (1) sekvencu propeptida koja sadrži aktivacijsku peptidnu sekvencu elastaze koja sadrži aminokiseline označene P10-P9-P8-P7-P6-P5-P4-P3-P2-P1, od kojih su aminokiseline P3-P2- P1 napravljene da formiraju sekvencu prepoznavanja elastaze, operativno povezanu na (ii) aminokiselinsku sekvencu zrelog tipa I elastaze čije su tri N-terminalne aminokiseline označene P1'- P2'- P3', naznačen time da (a) sekvenca propeptida nije porijeklom iz zrelog tipa I elastaze, i
The modified FIX polypeptide can be formulated for oral, parenteral or rectal administration, or in forms suited to administrations by inhalation or insufflation (either via the mouth or nose). 
Polipeptid za uporabu sukladno zahtjevu 8, naznačen time, da je navedeni farmaceutski pripravak formuliran za oralnu, parenteralnu, rektalnu upotrebu, inhalacijsku ili upuhivanjem.
The kit of claim 1, wherein the specified period starts at 72-12 hours prior to the medical procedure. 
Komplet iz patentnog zahtjeva 1, pri tome navedeni period počinje od 72-12 sati prije medicinskog postupka.
performing a reading of the code of the request and cross-checking the validity of the request itself by asking an acknowledgment to the external data-management system; and 
- < obavljanje čitanja koda zahtjeva 1 unakrsno ispitivanje vrijednosti samog zahtjeva ispitivanjem potvrde vanjskog sustavu za vođenje podataka (17);
These openings are closed with a sealing strip 50 having an engagement tab 51 for peeling of lip 50. 
Ovi otvori su zatvoreni s trakom za zatvaranje 50, koja traka ima jedan jezičac za prihvaćanje 51, pomoću kojega se odvoji ovaj jezičac.
A cementitious binder according to claim 1, which consists of GGBS, PFA or the mixture of GGBS and PFA, the CaO or lime and the superplasticiser. 
Cementno vezivo prema zahtjevu 1, naznačeno time što hidraulički aktivan materijal sadrži barem 50% ili 70% ili 80% ili 90% GGBS, PFA ili smjesu GGBS i PFA.
contacting a test compound with a host cell or with membrane of a host cell that expresses a G protein-coupled receptor, wherein the G protein-coupled receptor comprises an amino acid sequence selected from the group consisting of: 
(a) stavljanje u kontakt test spoja sa stanicom domačina ili membranom stanice domaćina koja izlučuje G protein-kupiran receptor pri čemu navedeni G protein kupirani receptor obuhvaća aminokiselinsku sekvencu izabranu iz skupine koju čine:
contacting said biological sample with an antibody of any one of claims 1-3, wherein said antibody is conjugated or covalently bound to a detectable moiety; and 
kontakt biološkog uzorka s protutijelom ili fragmentom protutijela prema zahtjevu 57, gdje je to protutijelo ili fragment protutijela konjugirano ili kovalento vezano za spoj koji se može detektirati; i
that the mobile communication technology is one out of the following: 
Postupak prema jednom od prethodnih zahtjeva, pri čemu je mobilna komunikacijska tehnologija jedna od slijedećih:
In an exemplary embodiment, the patients are pregnant female opiate addicts on stable methadone maintenance therapy. 
U primjeru uobličenja, pacijenti su trudne opijatne ovisnice na stabilnoj terapiji održavanja metadonom.
The innerspring assembly of claim 8, wherein adjacent spring coils are connected either with adhesive; or with at least one of a hog ring and other metal fasteners. 
Sklop unutarnjih opruga iz zahtjeva 8, pri čemu su susjedne zavojnice spojene adhezivom; ili barem jednim kliještima 1 drugim metalnim pričvršćivačima.
The apparatus of claim 1, wherein the sensor comprises a timer and at least one of a current sensor, a voltage sensor, or a flow sensor; and wherein the data from the sensor comprises at least one of a current measurement of the first release device, a current measurement of a power supply, a voltage measurement of the first release device, a voltage measurement of the power supply, or an air speed measurement. 
Metoda sukladno zahtjevu 10, naznačena time da senzor (240, 291, 292, 293, 294, 295) sadrži barem jedan senzor protoka, termoelement, senzor tlaka, senzor struje (293, 294), senzor napona 1 senzor svjetla (295); i pri čemu uređaj za prvo oslobađanje (118) sadrži barem jedan grijaći element, generator vibracija, ultrazvučni pretvarač, piezoelektrični pretvarač i raspršivač.
The composition according to any one of claims 1 to 3, wherein the photoactivator further comprises a xanthene dye selected from pyronine Y, pyronine B, rhodamine B, rhodamine G, rhodamine WT, fluorescein, phloxine B, rose bengal, merbromine, eosin B and erythrosine B. The composition according to any one of claims 1 to 4, wherein the photoactivator further comprises an azo dye selected from methyl violet, neutral red, para red, amaranth, carmoisine, allura red AC, tartrazine, orange G, ponceau 4R, methyl red, and murexideammonium purpurate. The composition according to any one of claims 1 to 5, wherein the photoactivator further comprises a biological stain selected from saffranin O, basic fuchsin, acid fuschin, 3,3' dihexylocarbocyanine iodide, carminic acid, and indocyanine green. 
Kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 1 do 4, gdje fotoaktivator dalje sadrži floksin B, eozin B, bengal roze, fluorescein, eritrozin B, rodamin B, rodamin G, rodamin WT, smjesu praha crvenog šafrana, anato ekstrakt, i ekstrakt smeđe alge, šafranin O, bazni fuksin, kiseli fuksin, 3,3'-diheksilokarbocijanin jodid, karminsku kiselinu, indocijanin zelenu, krocetin, a-krocin (8,8-diapo-8,8-karotenska kiselina), zeaksantin, likopen, a-karoten, B-karoten, biksin, fukoksantin, metil ljubičastu, neutralno crvenu, krv crvenu, amarant, karmoizin, alura crvenu AC, tartrazin, narančastu G, ponso 4R, metil crvenu, mureksid-amonij purpurat, pironin Y i pironin B. Kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 1 do 5, gdje kompozicija dalje sadrži najmanje jedan helatni agens odabran od etilen diamintetraoctene kiseline (EDTA) i etilen glikol tetraoctene kiseline (EGTA).
Alternatively, after the addition of the cPCC to the aqueous medium, and the subsequent separation of the composites formed of cPCC, organic material and optional further materials from the aqueous medium, the turbidity of the aqueous medium is reduced compared to the turbidity of an aqueous medium without the use of the cPCC, and the chemical oxygen demand (COD) of the aqueous medium is reduced compared to the COD of an aqueous medium without the use of the cPCC, and the electrochemical charge (SCD) of the aqueous medium is increased compared to the electrochemical charge of an aqueous medium without the use of the cPCC. 
HR P20190392 T1 a) -mutnoća vodenog medija je smanjena u usporedbi s mutnoćom vodenog medija bez upotrebe cPCC, i/ili b) "kemijska potražnja za kisikom (COD) vodenog medija je smanjena u usporedbi s COD vodenog medija bez upotrebe cPCC, i/ili c) elektrokemijski naboj (SCD) vodenog medija je povećan u usporedbi s elektrokemijskim nabojem vodenog medija bez upotrebe cPCC. 15.
The invention pertains to a pharmaceutical composition, comprising one or more of the compounds or a pharmaceutically acceptable salt or hydrate thereof, wherein 
HR P20171829 T1 HR P20171829 T1 PATENTNI ZAHTJEVI 1. - Farmaceutski pripravak, koja sadrži jedno ili više od slijedećih spojeva
The compound of claim 6, wherein R41 is selected from the group consisting of —H, methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, ethoxy, propoxy, and cyclopropoxy. 
Spoj prema zahtjevu 19, pri čemu je R4, izabran iz skupine koju čine -H, metil, etil, propil, izopropil, ciklopropil, metoksi, etoksi, propoksi 1 ciklopropoksi.
the plurality of arched legs allows flexibility in key anatomic locations, the profile cross section of the leg being configured to allow bending along its thin dimension, while maintaining a relatively large area of contact in its long dimension, so as to conform to an individual user's nostril(s); and 
veći broj lučnih krakova dopušta fleksibilnost u ključnim anatomskim lokacijama, gdje je profil poprečnog presjeka kraka konstruiran da omogući savijanje uzduž njegove tanke dimenzije, dok se pritom održava relativno veliko područje kontakta u njegovoj dužoj dimenziji;
More specifically, the crude harvest of r-hIL6-IL6R chimera produced in CHO cells was loaded onto a MEP HYPERCEL® column equilibrated with PBS. 
Specifičnije, sirovi materijal sa himernim r-hIL6-IL6R nanesen je na kolonu MEP HyperCel ekvilibriranu sa PBS-om.
which contains the pharmacologically active agent according to general formula (I) in a dose of from 150 ug to 800 ug, preferably more than 190 ug to 800 ug; and 
koji sadrži farmakološki aktivno sredstvo prema općoj formuli (I) u dozi od 400+150 ug, izraženo kao težinska ekvivalentna doza bazirana na slobodnoj bazi; i -
In certain embodiments, oligonucleotide decoys comprising a deletion of one or more nucleotides selected from the group consisting of n2, n3 and n20 have at least 80% identity to the nucleotide sequence of SEQ ID NO.: 49. 
(c) sekvencu koja obuhvaća barem 85% identiteta sekvence od SEQ ID NO:42 i sadrži jedno ili više mjesta spajanja faktora transkripcije.
These compounds could also be used for the improvement of cognitive function (e.g., the treatment of dementia, including Alzheimer's disease, short term memory loss and attention deficit disorders); neurodegenerative disorders (e.g., Parkinson's Disease, cerebral apoplexy and craniocerebral trauma) and hypotension (e.g., hemorrhagic and endotoxin-inducd hypotension). 
Ovi se spojevi također mogu upotrijebiti za poboljšanje kognitivne funkcije (npr., liječenje demencije, što uključuje Alzheimerovu bolest, kratkotrajan gubitak pamćenja i poremećaje smanjene koncentracije); neurodegenerativne bolesti (npr., Parkinsonova bolest, cerebralna apopleksija i kraniocerebralna trauma) i hipotenzija (npr., hemorargija i hipotenzija uzrokovana endotoksinom).